Jefferies analyst Andrew Tsai raised the firm’s price target on Alto Neuroscience (ANRO) to $25 from $15 and keeps a Buy rating on the shares. Investor confidence in Alto’s precision psychiatry approach could rise in 2026 as ALTO-101 has Phase II data in Q1 2026 for CIAS, ALTO-300 has full Phase IIb data in mid-2026 in MDD depression, ALTO-100 has Phase IIa data in BPD depression in the second half of 2026, and as investors seem most keen on ALTO-207, whose Phase IIb timelines were recently accelerated.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Buy Recommendation for Alto Neuroscience Driven by Promising ALTO-207 Acquisition and Strategic Financial Backing
- Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment?
- Alto Neuroscience’s ALTO-300 Study: A Potential Game-Changer in Depression Treatment
- Alto Neuroscience’s ALTO-100 Study: A Potential Game-Changer for Bipolar Disorder Treatment?
- Alto Neuroscience’s Strategic Advancements and Regulatory Milestones Justify Buy Rating